December 15, 2023 10:47 AM EST

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

AC Immune’s anti-pTau drug enters PhIIb: The Swiss biotech’s partner Johnson & Johnson launched the “potentially registration-enabling” study of ACI-35.030 in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

AC Im­mune's Alzheimer's drug heads to PhI­Ib; Cy­to­Dyn HIV drug on full hold; Syn­dax to raise $200M

News Reporter

Senior Reporter

Deputy Editor

Sign up to read this article for free.

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M